803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer

BackgroundOver 20,000 women are diagnosed with ovarian cancer annually, and more than half will die within 5 years. This rate has changed little in the last 30 years, highlighting the need for therapy innovation. T cells engineered to express a T cell receptor (TCR) targeting proteins uniquely overe...

Full description

Bibliographic Details

Published in:	Journal for immunotherapy of cancer Vol. 11; no. Suppl 1; p. A902
Main Authors:	Anderson, Kristin G, Su, Yapeng, Burnett, Madison G, Bates, Breanna M, Suarez Gutierrez, Magdalia L, Ruskin, Susan L, Voillet, Valentin, Gottardo, Raphael, Greenberg, Philip D
Format:	Journal Article
Language:	English
Published:	London BMJ Publishing Group Ltd 01.11.2023 BMJ Publishing Group LTD BMJ Publishing Group
Subjects:	Cancer therapies Immunotherapy Lymphocytes Ovarian cancer Regular and Young Investigator Award Abstracts T cell receptors Tumors
ISSN:	2051-1426
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!